APLLTD

What Alembic Pharmaceuticals promised, and what happened

Every commitment management made on a call, tracked from the quarter it was made — reaffirmed, revised, diluted or quietly dropped.

Guidance record · Q4 FY26

what the last two calls moved 15 tracked 3 delivered 4 missed 8 open
  • ROW Business Growth delivered said Q4 FY25 Promised: between 12%, 15%, somewhere around there Q4 FY26: Full year Ex-U.S. markets grew 20%, meeting the revised 15-20% target.
  • Borrowing Level missed said Q2 FY25 Promised: hopefully, the borrowing level will be much lower by -- before end of the year Q4 FY26: Gross debt reported at ₹1,361 crores, remaining significantly elevated since the promise was made for FY25.
  • EBITDA Margin Target on track said Q4 FY25 Promised: 18%-19%-20% kind of EBITDA levels... over the next couple of years Q4 FY26: FY26 EBITDA margin was 17%. Management reiterates the long-term goal of 20% over 2-3 years, but current year performance is below the target range.

The rest of the ledger

Above is what the last two calls moved. Pro opens all 15 tracked commitments for Alembic Pharmaceuticals — every quarter's revision, the source quote behind each one, and the topics management has stopped answering.

See what Pro opens